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Surgical resection with wide safety margins (1.5Y2 cm) represents the conventional treatment. 3 However, even after achieving negative margins, recurrence rates are high, ranging from 20% to 60%. 4 Because this treatment alters the normal vulvar anatomy and function, more conservative treatments are being investigated. Recently, 5% imiquimod cream has been suggested as an alternative for the initial management of the primary disease as well as for recurrences. It is considered a safe and effective treatment. 5 
MATERIALS AND METHODS
We describe a case series that includes 10 women with histologic diagnosis of extramammary Paget disease of the vulva, who were selected for clinical treatment; of them, 3 were treated for recurrent disease and 7 were treated for initial primary disease.
All the patients had immunohistochemistry that confirmed primary vulvar Paget disease.
Approval of the ethics committee of the Hospital Italiano, Buenos Aires, was obtained to conduct this observational and prospective study, taking into account that this is an off-label use of 5% imiquimod cream.
The patients included in this study had declined surgery and signed an informed consent where it was stated that this therapy is not guaranteed to treat extramammary Paget disease.
All suspicious lesions such as ulcers, nodules, or indurated areas were sampled by biopsy and submitted for histopathologic examination to rule out invasive disease or underlying adenocarcinoma. Skin, gynecologic, and breast examinations were carried out, as well as a urological evaluation in patients with periurethral lesions (including cystoscopy) and a coloproctologic evaluation in patients with perianal lesions (by performing a colonoscopy).
The patients applied 5% imiquimod cream on the lesions and up to 2 cm outside their visible margins every other day. They were previously instructed on how and where to apply the cream by making them use a mirror while following the physician's directions.
Monthly checkups were scheduled after starting the treatment until the clinical disappearance of the disease. Histologic examination of the treated area was carried out 2 months after having finished the treatment to avoid diagnostic difficulties associated with the inflammatory response generated by imiquimod.
Three of the patients, aged 63, 64, and 60 years old, respectively, had recurrent Paget disease of the vulva after several surgical treatments. Clinical disappearance of the disease was observed 4 months after starting treatment, and biopsies of the treated area were negative for Paget disease in all 3 patients. Currently, they all remain disease free, with a follow-up of 42, 31, and 49 months, respectively (see Table 1 ).
The 7 remaining patients, aged between 60 and 92 years old, had initial primary Paget disease of the vulva. The 92-yearold patient (see Figure 6 ) presented an indurated, raised lesion on the left labium majus, which was resected, thus ruling out invasive disease and underlying adenocarcinoma. All 7 patients were treated with 5% imiquimod cream, as explained above, until clinical disappearance of the disease. Six patients showed a complete response, with negative biopsies for Paget disease. The 92-year-old patient showed partial response and is still under treatment. Length of treatment varied from 5 to 7 months, and the follow-up ranged between 3 and 5 months for this group (see Table 1 ; patients 4 to 10).
RESULTS
Complete clinical and histologic remission of the disease was achieved in 9 patients. The remaining patient, who belonged to the group of patients with initial primary Paget disease, had a partial histologic response and is still under treatment (see Table 1 ).
Only local adverse effects were observed in the study group, which were moderate local irritation and some erosion, both of which were well tolerated by patients.
No recurrences were observed during a mean follow-up of 18 months (see Figures 1Y6) .
DISCUSSION
Several treatments, each with variable effectiveness, are available to treat the disease, namely laser surgery, aminolevulinic acid photodynamic therapy, radiotherapy, topical chemotherapy, and wide surgical excision. Although surgery is generally accepted as the standard form of treatment, all surgical procedures, including extensive resections, are associated with high rates of recurrence (20%Y60%). 4 Therefore, there has been a shift toward a more conservative approach; thus, the treatment that offers both a low recurrence rate and minimal tissue destruction is considered to be the ideal one. A topical immunomodulator that induces cytokine production and stimulates the innate and cellular immune response (imiquimod cream) has recently been used for the treatment of primary or recurrent Extramammary Paget disease, showing complete eradication, without recurrence. 6, 7 Imiquimod is an immune response modifier that stimulates the production of a wide range of cytokines, interferon-> and tumor necrosis factor->. Being an agonist of toll-like receptors, it leads to the combined activation of innate local immunity and T H 1 immune response as well as to the inhibition of T H 2 cytokines, which are overexpressed in skin cancer. Imiquimod may also have direct antineoplastic activity, encouraging migration of Langerhans cells, inducing apoptosis, and inhibiting tumor-associated angiogenesis. However, the mechanism of action by which imiquimod promotes tumor eradication in extramammary Paget disease remains to be determined. 8 Topical therapy with imiquimod cream is suggested as a safe and effective treatment option for this condition.
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Since imiquimod was first described to treat primary vulvar extramammary Paget disease by Wang et al. in 2003, 7 29 additional cases have been documented with variable outcomes (see Table 2 ). Of all the primary disease cases (n = 12), 50% have achieved clinical resolution with imiquimod therapy alone. Of the recurrent primary disease cases (n = 15), 73% have achieved clinical resolution with imiquimod therapy alone. 
CONCLUSIONS
Topical imiquimod was an effective treatment both for recurrent and for initial primary vulvar Paget disease in 9 of the 10 patients presented herein. It proved to be a safe and effective option for the treatment of vulvar Paget disease, especially in those patients with extensive lesions or those at high risk for surgical treatment because of comorbidities. Surgical excision or an alternative therapeutic option can be reserved for those patients whose extramammary Paget disease persists or recurs after topical treatment with imiquimod. However, it should be kept in mind that because of the low prevalence of the disease, the small number of cases reported in different series, and the poor longterm follow-up, it is difficult to determine the real effectiveness of topical imiquimod therapy. Moreover, the number of cases published is too limited to allow generalizations. Obviously, the promising results obtained must be validated with clinical trials, which should evaluate not only the efficacy and safety of the treatment but also the most appropriate treatment course. Therefore, treatment with topical imiquimod is still considered to be a very promising therapy for this rare disease.
